Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: 5-hydroxyindolacetic acid in urine increased, Alanine aminotransferase normal, Blood albumin normal, Blood creatinine decreased, Blood glucose normal
Clinical narrative: had blurred vision; heart palpitations; a metallic taste; suffered with debilitating fatigue; malaise; brain fog; insomnia; leg weakness (jelly legs); numbness; tingling; burning; muscle loss; weight loss; vision issues; balance issues; ear issues; joint pain; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 31 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 29Jan2021 11:30 (Lot number: EN5318) at the age of 31 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "drug allergy" (unspecified if ongoing), notes: Relevant past drug history , Name of Drug as Reported: No, Reaction: Allergy. The patient took concomitant medications. Vaccination history included: Bnt162b2 (Dose Number: 1 Batch/Lot No: EL0142 Location of injection: Arm Left Vaccine Administration Time: 11:30 AM), administration date: 08Jan2021. The following information was reported: VISION BLURRED (disability) with onset 03Feb2021, outcome "not recovered", described as "had blurred vision"; PALPITATIONS (disability) with onset 03Feb2021, outcome "not recovered", described as "heart palpitations"; DYSGEUSIA (disability) with onset 03Feb2021, outcome "not recovered", described as "a metallic taste"; FATIGUE (disability) with onset 03Feb2021, outcome "not recovered", described as "suffered with debilitating fatigue"; MALAISE (disability) with onset 03Feb2021, outcome "not recovered", described as "malaise"; FEELING ABNORMAL (disability) with onset 03Feb2021, outcome "not recovered", described as "brain fog"; INSOMNIA (disability) with onset 03Feb2021, outcome "not recovered", described as "insomnia"; MUSCULAR WEAKNESS (disability) with onset 03Feb2021, outcome "not recovered", described as "leg weakness (jelly legs)"; HYPOAESTHESIA (disability) with onset 03Feb2021, outcome "not recovered", described as "numbness"; PARAESTHESIA (disability) with onset 03Feb2021, outcome "not recovered", described as "tingling"; BURNING SENSATION (disability) with onset 03Feb2021, outcome "not recovered", described as "burning"; MUSCLE ATROPHY (disability) with onset 03Feb2021, outcome "not recovered", described as "muscle loss"; WEIGHT DECREASED (disability) with onset 03Feb2021, outcome "not recovered", described as "weight loss"; VISUAL IMPAIRMENT (disability) with onset 03Feb2021, outcome "not recovered", described as "vision issues"; BALANCE DISORDER (disability) with onset 03Feb2021, outcome "not recovered", described as "balance issues"; EAR DISORDER (disability) with onset 03Feb2021, outcome "not recovered", described as "ear issues"; ARTHRALGIA (disability) with onset 03Feb2021, outcome "not recovered", described as "joint pain". The events "had blurred vision", "heart palpitations", "a metallic taste", "suffered with debilitating fatigue", "malaise", "brain fog", "insomnia", "leg weakness (jelly legs)", "numbness", "tingling", "burning", "muscle loss", "weight loss", "vision issues", "balance issues", "ear issues" and "joint pain" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (10Sep2021) negative. Therapeutic measures were not taken as a result of vision blurred, palpitations, dysgeusia, fatigue, malaise, feeling abnormal, insomnia, muscular weakness, hypoaesthesia, paraesthesia, burning sensation, muscle atrophy, weight decreased, visual impairment, balance disorder, ear disorder, arthralgia. Additional information: The patient had no known allergies and no other medical history. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Within 2 weeks of vaccination, the patient had prenatal medications. The patient immediately had blurred vision, heart palpitations, and a metallic taste. The patient then suffered with debilitating fatigue, malaise, brain fog, insomnia, leg weakness (jelly legs), numbness and tingling, burning, muscle loss, weight loss, vision issues, balance issues, ear issues, joint pain and have had bouts of being unable to work since vaccination. The events resulted in: Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, disability, or permanent damage.; Sender's Comments: Based on the information provided a causal association between the events and the suspect product BNT162B2 cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate